Sign In
Buy ALC
$64.22
-0.0600 (-0.0933%)
At Close: Jun 03, 2026
Aerie set to be bought by Alcon for $770 million
04:30pm, Tuesday, 23'rd Aug 2022
New Jersey-based biotech firm Aerie is seeing its shares move higher amid news of it being bought by Aerie Pharmaceuticals.
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
09:38am, Tuesday, 23'rd Aug 2022
Alcon will buy glaucoma drugs maker Aerie Pharmaceuticals in a $770 million deal that sent the biotech stock flying Tuesday. The post Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aeri
Alcon to Acquire Aerie Pharmaceuticals for $15.25 a Share
03:45am, Tuesday, 23'rd Aug 2022
Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share.
Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered
11:18am, Thursday, 11'th Aug 2022
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.
Alcon Inc. (ALC) CEO David Endicott on Q2 2022 Results - Earnings Call Transcript
12:43pm, Wednesday, 10'th Aug 2022
Alcon Inc. (NYSE:ALC ) Q2 2022 Results Conference Call August 10, 2022 8:00 AM ET Company Participants Dan Cravens - VP and Global Head IR David Endicott - CEO Tim Stonesifer - CFO Conference Call Par
Alcon's (ALC) Product Launches, Market Recovery Aid Growth
12:24pm, Monday, 18'th Jul 2022
Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.
Here's Why Alcon (ALC) is a Strong Momentum Stock
11:36am, Monday, 11'th Jul 2022
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Investors Should Retain Alcon (ALC) Stock For Now
02:02pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.
Here's Why Investors Should Retain Alcon (ALC) Stock For Now
11:17am, Thursday, 09'th Jun 2022
Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.
Alcon: Revisiting The Investment Thesis
01:13am, Friday, 03'rd Jun 2022
Alcon continues to grow at a double-digit rate and is on track to achieve management's full-year guidance. Both the Surgical and the Vision Care segments delivered double-digit growth, which highligh
Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals
03:28pm, Monday, 23'rd May 2022 Zacks Investment Research
The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.
Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals
12:48pm, Monday, 23'rd May 2022
The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.
Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow
05:16pm, Thursday, 12'th May 2022 Zacks Investment Research
Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.
Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow
02:18pm, Thursday, 12'th May 2022
Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2022
02:04pm, Thursday, 12'th May 2022 Benzinga
Upgrades
For Warner Bros.Discovery Inc (NASDAQ:WBD), Cowen & Co. upgraded the previous rating of Market Perform to Outperform. The current stock performance of Warner Bros.Discovery shows a 52-week-h
